Boston Scientific
Official SEC filings
Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 01:43 UTC.
| Form | Filed | Original document |
|---|---|---|
| 8-K | 2026-11-20 | Read on SEC.gov |
| 8-K | 2026-11-17 | Read on SEC.gov |
| 10-Q | 2026-11-02 | Read on SEC.gov |
| 8-K | 2026-10-28 | Read on SEC.gov |
| 8-K | 2026-10-07 | Read on SEC.gov |
| 8-K | 2026-09-23 | Read on SEC.gov |
| 8-K | 2026-09-08 | Read on SEC.gov |
| 8-K | 2026-08-26 | Read on SEC.gov |
SEC annual financial snapshot
Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-21 09:51 UTC.
| Metric | USD | Basis | Period end | Filed | Source |
|---|---|---|---|---|---|
| Revenue | $20.07B | Annual | 2025-12-31 | 2026-02-17 | 10-K |
| Net income | $2.89B | Annual | 2025-12-31 | 2026-02-17 | 10-K |
| Operating cash flow | $4.53B | Annual | 2025-12-31 | 2026-02-17 | 10-K |
| Total assets | $43.67B | As of | 2025-12-31 | 2026-02-17 | 10-K |
| Stockholders’ equity | $24.23B | As of | 2025-12-31 | 2026-02-17 | 10-K |
| Cash and cash equivalents | $1.97B | As of | 2025-12-31 | 2026-02-17 | 10-K |
✦ Quant Financial Health how this is computed
- Altman Z-Score is 2.93, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
✦ Quant Revenue Concentration how this is computed
- Cardiovascular is the largest reported line at 66.29% of revenue, across 3 reported segments.
- MedSurg follows at 33.77%, so the top line still matters most but isn’t the whole story.
Revenue annual, last 8 years
Latest year +19.87% YoY
Margins
- Gross margin
- 69.01%
- Operating margin
- 19.78%
- Net margin
- 14.44%
Key ratios & quality
- Enterprise valuei
- 70.19B
- PEG ratioi
- 0.29
- Altman Z-Scorei
- 2.93
PEG uses trailing P/E against the 3-year net income growth rate (60.72%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.82B | 10.74B | 9.91B | 11.89B | 12.68B | 14.24B | 16.75B | 20.07B |
| Gross profit | 6.94B | 7.55B | 6.40B | 8.18B | 8.73B | 9.90B | 11.49B | 13.85B |
| Selling & admin expenses | 3.57B | 3.94B | 3.79B | 4.36B | 4.52B | 5.19B | 5.98B | 6.89B |
| Research & development | 1.11B | 1.17B | 1.14B | 1.20B | 1.32B | 1.41B | 1.62B | 2.05B |
| Operating profit | 1.66B | 1.74B | 684.00M | 1.82B | 2.03B | 2.42B | 3.00B | 3.97B |
| Pretax profit | 1.42B | 687.00M | -79.00M | 1.08B | 1.14B | 1.99B | 2.28B | 3.39B |
| Tax | -249.00M | -4.01B | 2.00M | 36.00M | 443.00M | 393.00M | 436.00M | 493.00M |
| Net profit | 1.67B | 4.70B | -82.00M | 1.04B | 698.00M | 1.59B | 1.85B | 2.89B |
| Basic EPS | 1 | 3 | 0 | 1 | 0 | 1 | 1 | 2 |
| Diluted EPS | 1.19 | 3.33 | -0.08 | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 5.06B | 5.07B | 5.29B | 5.20B | 5.44B | 5.14B |
| Gross profit | 3.42B | 3.54B | 3.68B | 3.61B | 3.85B | 3.43B |
| Selling & admin expenses | 1.72B | 1.74B | 1.83B | 1.78B | 1.80B | 1.68B |
| Research & development | 526.00M | 514.00M | 569.00M | 516.00M | 554.00M | 520.00M |
| Operating profit | 943.00M | 1.05B | 1.04B | 1.07B | 1.25B | 979.00M |
| Pretax profit | 941.00M | 939.00M | 700.00M | 1.16B | 1.06B | 733.00M |
| Tax | 146.00M | 183.00M | 30.00M | -176.00M | 155.00M | 153.00M |
| Net profit | 795.00M | 755.00M | 670.00M | 1.34B | 905.00M | 580.00M |
| Basic EPS | 1 | 1 | 0 | 1 | 1 | 0 |
| Diluted EPS | 0.53 | 0.51 | 0.45 | 0.90 | 0.61 | 0.40 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 4.00B | 4.70B | 6.69B | 6.32B | 5.76B | 6.51B | 6.92B | 8.79B |
| Cash & ST investments | 146.00M | 217.00M | 1.73B | 1.93B | 928.00M | 865.00M | 414.00M | 1.97B |
| Inventory | 1.17B | 1.58B | 1.35B | 1.61B | 1.87B | 2.48B | 2.81B | 2.94B |
| Total assets | 21.00B | 30.57B | 30.78B | 32.23B | 32.47B | 35.14B | 39.40B | 43.67B |
| Total current liabilities | 5.26B | 4.87B | 3.68B | 4.27B | 3.80B | 4.93B | 6.40B | 5.44B |
| Short-term debt | 2.25B | 1.42B | 13.00M | 261.00M | 20.00M | 531.00M | 1.78B | 299.00M |
| Long-term debt | 4.77B | 8.58B | 9.12B | 8.80B | 8.91B | 8.57B | 8.84B | 11.01B |
| Total liabilities | 12,273,000,000.00 | 16,688,000,000.00 | 15,451,000,000.00 | 15,607,000,000.00 | 14,896,000,000.00 | 15,606,000,000.00 | 17,392,000,000.00 | 19,201,000,000.00 |
| Total equity | 8.73B | 13.88B | 15.33B | 16.62B | 17.57B | 19.53B | 22.00B | 24.47B |
| Retained earnings | -6.95B | -2.25B | -2.38B | -1.39B | -750.00M | 819.00M | 2.67B | 5.57B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 7.12B | 8.04B | 8.79B | 8.68B | 7.97B | 8.16B |
| Cash & ST investments | 534.00M | 1.28B | 1.97B | 1.45B | 539.00M | 609.00M |
| Inventory | 2.86B | 2.92B | 2.94B | 3.12B | 3.24B | 3.32B |
| Total assets | 41.56B | 42.71B | 43.67B | 44.35B | 45.22B | 45.46B |
| Total current liabilities | 5.19B | 5.33B | 5.44B | 4.57B | 6.43B | 5.98B |
| Short-term debt | 480.00M | 483.00M | 299.00M | 41.00M | 1.71B | 1.04B |
| Long-term debt | 10.98B | 10.99B | 11.01B | 10.86B | 10.79B | 10.79B |
| Total liabilities | 18,906,000,000.00 | 19,077,000,000.00 | 19,201,000,000.00 | 18,247,000,000.00 | 20,044,000,000.00 | 19,588,000,000.00 |
| Total equity | 22.65B | 23.63B | 24.47B | 26.10B | 25.17B | 25.87B |
| Retained earnings | 4.14B | 4.90B | 5.57B | 6.91B | 7.82B | 8.40B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 310.00M | 1.84B | 1.51B | 1.87B | 1.53B | 2.50B | 3.44B | 4.53B |
| Depreciation & amortization | 894.00M | 1.01B | 1.12B | 1.09B | 1.14B | 1.20B | 1.27B | 1.37B |
| Free cash flow | -178.00M | 1.38B | 1.13B | 1.32B | 914.00M | 1.70B | 2.37B | 3.40B |
| Dividends paid | 0 | 0 | -28.00M | -55.00M | -55.00M | -28.00M | 0 | -- |
| Stock buybacks / issuance | 0 | 0 | 440.00M | -- | -- | -- | -- | -- |
| Ending cash balance | 829.00M | 607.00M | 2.00B | 2.17B | 1.13B | 1.06B | 606.00M | 2.15B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.29B | 1.34B | 1.36B | 348.00M | 1.47B | 1.05B |
| Depreciation & amortization | 336.00M | 342.00M | 365.00M | 351.00M | 355.00M | 361.00M |
| Free cash flow | 1.04B | 1.09B | 999.00M | 171.00M | -451.00M | 797.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | -- | -- | -- | 0 |
| Ending cash balance | 741.00M | 1.48B | 2.15B | 1.64B | 753.00M | 797.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 21.24 | 41.59 | -0.79 | 6.17 | 3.75 | 8.52 | 9.03 | 12.60 |
| ROA %i | 8.35 | 18.23 | -0.37 | 3.13 | 1.98 | 4.64 | 4.97 | 6.98 |
| ROIC %i | 13.00 | 25.17 | 0.95 | 5.15 | 3.49 | 6.35 | 6.53 | 9.25 |
| 5-year avg ROE %i | 4.50 | 13.18 | 13.77 | 13.94 | 14.39 | 11.85 | 5.34 | 8.01 |
| EBIT margin %i | 16.93 | 10.81 | 2.84 | 11.92 | 12.70 | 15.80 | 15.45 | 18.60 |
| FCF / sales %i | -- | 11.42 | 9.95 | 11.07 | 7.40 | 11.96 | 14.12 | 16.96 |
| Current ratioi | 0.76 | 0.97 | 1.82 | 1.48 | 1.51 | 1.32 | 1.08 | 1.62 |
| Quick ratioi | 0.34 | 0.42 | 0.89 | 0.87 | 0.76 | 0.63 | 0.46 | 0.90 |
| Debt / assetsi | 33.48 | 33.62 | 30.99 | 29.32 | 28.59 | 27.02 | 27.28 | 26.19 |
| LT debt / equityi | 54.75 | 63.85 | 62.15 | 55.28 | 52.70 | 46.48 | 41.19 | 45.96 |
| Interest coveragei | 6.90 | 2.45 | 0.78 | 4.16 | 3.43 | 8.49 | 8.48 | 10.70 |
| Revenue CAGR (3Y) %i | 9.52 | 8.58 | 3.09 | 6.57 | 5.71 | 12.83 | 12.10 | 16.54 |
| Net income CAGR (3Y) %i | -- | 138.37 | -- | -14.59 | -47.04 | -- | 21.21 | 60.72 |
| FCF CAGR (3Y) %i | -- | 26.83 | 5.07 | -- | -12.73 | 14.58 | 21.58 | 55.01 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 11.71 | 12.66 | 12.60 | 14.83 | 15.52 | 14.29 |
| ROA %i | 6.37 | 6.91 | 6.98 | 8.44 | 8.47 | 7.94 |
| ROIC %i | 8.46 | 9.14 | 9.25 | 11.03 | 11.16 | 10.57 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 18.01 | 18.65 | 18.60 | 19.88 | 20.12 | 19.13 |
| FCF / sales %i | 17.49 | 18.75 | 16.96 | 16.00 | 8.60 | 7.20 |
| Current ratioi | 1.37 | 1.51 | 1.62 | 1.90 | 1.24 | 1.36 |
| Quick ratioi | 0.65 | 0.77 | 0.90 | 0.98 | 0.56 | 0.62 |
| Debt / assetsi | 28.94 | 28.21 | 26.19 | 24.87 | 27.92 | 26.29 |
| LT debt / equityi | 51.51 | 49.43 | 45.96 | 42.48 | 43.78 | 42.56 |
| Interest coveragei | 10.06 | 10.65 | 10.70 | 11.48 | 11.64 | 10.75 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Boston Scientific discussion 0 comments